Annual report pursuant to Section 13 and 15(d)

Nature of Business, Basis of Presentation, Going Concern and Liquidity - Additional Information (Detail)

v3.19.1
Nature of Business, Basis of Presentation, Going Concern and Liquidity - Additional Information (Detail)
3 Months Ended 12 Months Ended
May 23, 2018
Aug. 01, 2017
shares
Dec. 31, 2018
USD ($)
Product
Sep. 30, 2018
USD ($)
Jun. 30, 2018
USD ($)
Mar. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Sep. 30, 2017
USD ($)
Jun. 30, 2017
USD ($)
Mar. 31, 2017
USD ($)
Dec. 31, 2018
USD ($)
Product
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Nature Of Business And Basis Of Presentation [Line Items]                          
Reverse stock split ratio 0.1                        
Number of products approved for commercial sale | Product     0               0    
Revenue from product sales                     $ 0    
Type of Revenue [Extensible List]                     us-gaap:ProductMember    
Net loss     $ (3,637,000) $ (3,240,000) $ (2,788,000) $ (3,022,000) $ (3,740,000) $ (6,469,000) $ (169,000) $ (205,000) $ (12,687,000) $ (10,583,000) $ (1,234,000)
Accumulated deficit     (25,381,000)       $ (12,694,000)       (25,381,000) $ (12,694,000)  
Cash, cash equivalents and short term investments     14,600,000               14,600,000    
Working capital     $ 12,300,000               $ 12,300,000    
OncoGenex Pharmaceuticals, Inc [Member]                          
Nature Of Business And Basis Of Presentation [Line Items]                          
Reverse stock split ratio   0.0909                      
Conversion of each issued share of Achieve common stock , shares converted | shares   821,011